✦ LIBER ✦

EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan

✍ Scribed by Fotios Loupakis, Chiara Cremolini, Anna Fioravanti, Paola Orlandi…

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Intergenic polymorphisms in the amphireg

✍ Sebio, A; Páez, D; Salazar, J; Berenguer-Llergo, A; Paré-Brunet, L; Lasa, A; del 📂 Article 📅 2013 🏛 Nature Publishing Group 🌐 English ⚖ 332 KB

MDR1polymorphism role in patients treate

✍ Bernard Paule; Vincent Castagne; Véronique Picard; Raphaël Saffroy; René Adam; C 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 210 KB

Markers for EGFR pathway activation as p

✍ Jolien Tol; Jeroen R. Dijkstra; Marjolein Klomp; Steven Teerenstra; Martin Domme 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 559 KB

6119 Triple mutational testing for respo

✍ Spindler, K.; Pallisgaard, N.; Lindebjerg, J.A.N.; Jakobsen, A. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 68 KB

Comparison of EORTC Criteria and PERCIST

✍ Skougaard, K.; Nielsen, D.; Jensen, B. V.; Hendel, H. W. 📂 Article 📅 2013 🏛 The Society of Nuclear Medicine 🌐 English ⚖ 663 KB

1086 Cetuximab in a randomized phase II

✍ Van Cutsem, E.; Gascón Vilaplana, P.; Seitz, J.F.; Van Laethem, J.L.; Grossi, F. 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 159 KB